Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039248-11
Application #
2089795
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1985-05-01
Project End
1998-11-30
Budget Start
1995-12-01
Budget End
1996-11-30
Support Year
11
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107

  Publications

Coss, R A; Storck, C W; Wachsberger, P R et al. (2004) Acute extracellular acidification reduces intracellular pH, 42 degrees C-induction of heat shock proteins and clonal survival of human melanoma cells grown at pH 6.7. Int J Hyperthermia 20:93-106
Berd, David (2003) Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine. Vaccine 21:795-7
Coss, Ronald A; Storck, Christopher W; Daskalakis, Constantine et al. (2003) Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Mol Cancer Ther 2:383-8
Wahl, Miriam L; Owen, Judith A; Burd, Randy et al. (2002) Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617-28
Manne, Jayanthi; Mastrangelo, Michael J; Sato, Takami et al. (2002) TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol 169:3407-12
Han, J-S; Storck, C W; Wachsberger, P R et al. (2002) Acute extracellular acidification increases nuclear associated protein levels in human melanoma cells during 42 degrees C hyperthermia and enhances cell killing. Int J Hyperthermia 18:404-15
Berd, David (2002) M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2:335-42
Berd, David; Sato, Takami; Mastrangelo, Michael J (2002) Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses. Cancer Immunol Immunother 51:320-6
Berd, D; Sato, T; Cohn, H et al. (2001) Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 94:531-9
Berd, D; Maguire Jr, H C; Schuchter, L M et al. (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-70

Showing the most recent 10 out of 37 publications